Comparison of intra-articular injection of parecoxib vs oral administration of celecoxib for the clinical efficacy in the treatment of early knee osteoarthritis

Table 1 Comparison of the baseline information of three groups

Group	Group A	Group B	Group C	F/χ2 value	P value
Case	37	37	36
Gender
Male	17	19	15	0.692	0.707
Female	20	18	21
Age in yr, mean ± SD	52.1 ± 4.7	51.7 ± 3.5	52.1 ± 4.2	0.150	0.86
Kellgren-Lawrence grade
Grade 0	5	8	6	0.91	0.923
Grade I	21	19	19
Grade II	11	10	11
Course of disease (mo)	4.7 ± 1.0	4.8 ± 0.9	4.9 ± 1.0	0.17	0.847
BMI (kg/m2)	24.8 ± 1.2	25.0 ± 1.3	24.9 ± 1.0	0.23	0.796
Occupation
Manual worker	26	27	25	0.121	0.941
Mental worker	11	10	11
Marital status
Married	35	36	35	0.498	0.779
Single	2	1	1
Education Level
Primary	5	4	4	0.41	0.982
Secondary	25	24	24
Higher	7	9	8
Underlying disease
HT/DM/CHD	10/3/2	11/4/3	9/1/1	1.415	0.842

BMI: Body mass index; HT: Hypertension; DM: Diabetes mellitus; CHD: Coronary heart disease.

Table 2 Comparison of visual analogue scale scores and satisfaction of patients in the three groups before and after treatment

Group	Case	VAS scores		Patients’ satisfaction degree: Satisfied/unsatisfied
		Before	After
Group A	37	4.1 ± 0.7	3.4 ± 0.6	8/29
Group B	37	4.0 ± 0.6	1.8 ± 0.6	33/4
Group C	36	4.1 ± 0.7	0.8 ± 0.5	35/1
F/χ2 value		0.09	179.97	59.38
P value		0.9102	< 0.001	< 0.001

Data are presented as mean ± SD. VAS: Visual analogue scale.

Table 3 Comparison of Hospital for Special Surgery Knee scores in the three groups before and after treatment

Group	Case	HSS scores before treatment							HSS scores before treatment
		Pain	Func-tion	Mobi-lity	Muscle tone	Flexion defor-mity	Stabi-lity	Total score	Pain	Function	Mobi-lity	Muscle tone	Flexion defor-mity	Stabi-lity	Total scores
Group A	37	16.7 ± 2.4	20.2 ± 0.6	14.5 ± 1.0	10	8.4 ± 0.8	9.7 ± 0.7	79.5 ± 2.8	19.0 ± 2.0	20.6 ± 0.9	14.8 ± 0.9	10	8.4 ± 0.8	9.7 ± 0.7	82.5 ± 2.5
Group B	37	16.9 ± 2.5	20.1 ± 0.5	14.5 ±1.2	10	8.6 ± 0.9	9.8 ± 0.6	79.9 ± 3.2	22.3 ± 4.0	21.3 ± 1.0	14.9 ± 1.1	10	8.6 ± 0.9	9.8 ± 0.6	86.9 ± 4.7
Group C	36	17.2 ± 2.5	20.2 ± 0.6	14.3 ± 1.0	10	8.4 ± 0.8	9.7 ± 0.8	79.7 ± 3.3	27.8 ± 2.5	21.5 ± 0.9	15.2 ± 1.0	10	8.4 ± 0.8	9.7 ± 0.8	92.5 ± 3.3
F value		0.34	0.39	0.8	-	0.77	0.31	0.14	80.27	9.67	1.12	-	0.77	0.31	69.17
P value		0.710	0.680	0.452	1	0.466	0.736	0.87	< 0.001	< 0.001a	0.329	1	0.466	0.736	< 0.001

^aIntergroup comparison of single item (Function item) of Hospital for Special Surgery after treatment: there were significant differences in group B and C compared with group A; there were no significant differences between group B and C. Data are presented as mean ± SD. HSS: Hospital for Special Surgery.

Table 4 Comparison of inflammatory cytokine levels in the synovial fluid in the three groups before and after treatment

Group	Case	IL-6 (pg/mL)		TNF-α (pg/mL)		IL-10 (pg/mL)
		Before	After	Before	After	Before	After
Group A	37	418.7 ± 27.8	384.1 ± 25.0b	3.66 ± 0.38	3.03 ± 0.28b	5.47 ± 0.32	6.04 ± 0.49b
Group B	37	415.7 ± 28.2	212.6 ± 23.4b	3.53 ± 0.47	2.07 ± 0.33b	5.52 ± 0.30	7.46 ± 0.44b
Group C	36	412.7 ± 37.1	137.8 ± 29.0b	3.56 ± 0.53	1.45 ± 0.26b	5.42 ± 0.43	8.72 ± 0.60b
F value		0.34	871.17	0.70	275.41	0.87	246.74
P value		0.715	< 0.001	0.497	< 0.001	0.422	< 0.001

^bComparison of interleukin-6, Tumor necrosis factor-α and interleukin-10 levels for each group before and after treatment, significant differences were found (P < 0.001). Data are presented as mean ± SD of pg/mL. IL-6: Interleukin-6; TNF-α: Tumor necrosis factor-α; IL-10: Interleukin-10.